Browse > Article
http://dx.doi.org/10.5765/jkacap.2011.22.4.253

An Open-Label Study of the Improvements in Clinical Symptoms and Neurocognitive Functions in Korean Children and Adolescents with Attention-Deficit Hyperactivity Disorder after Treatment with Metadate CD  

Yoo, Han-Ik K. (Seoul Brain Research Institute)
Kim, Bong-Seog (Department of Psychiatry, Sanggye Paik Hospital, College of Medicine, Inje University)
Joung, Yoo-Sook (Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Bahn, Geon-Ho (Department of Psychiatry, Kyung Hee University School of Medicine)
Song, Dong-Ho (Department of Child & Adolescent Psychiatry, Severance Children's Hospital and Institute for Behavioral Science in Medicine, Yonsei University College of Medicine)
Ahn, Dong-Hyun (Department of Psychiatry and Institute of Mental Health, Hanyang University College of Medicine)
Lee, Young-Sik (Department of Neuropsychiatry, Chung-Ang University College of Medicine)
Publication Information
Journal of the Korean Academy of Child and Adolescent Psychiatry / v.22, no.4, 2011 , pp. 253-261 More about this Journal
Abstract
Objectives : This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neuro-cognitive functions. Methods : Ninety-one subjects with ADHD (mean age 8.6${\pm}$2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug's effects. Results : After 0.92${\pm}$0.32mg/kg/day of MCD were administered for 57.4${\pm}$7.6 days, there was a 48.5% reduction in the mean total ARS scores (p<.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p<.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p<.05). The forward memory span of the spatial working memory test scores increased (p<.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%). Conclusion : This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.
Keywords
ADHD; Metadate CD; Effectiveness; Safety; Comprehensive Attention Test;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010;157:635-640, 640.e1.   DOI   ScienceOn
2 Hanisch C, Konrad K, Günther T, Herpertz-Dahlmann B. Age-dependent neuropsychological deficits and effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a comparison of pre- and grade-school children. J Neural Transm 2004;111:865-881.
3 Fan J, McCandliss BD, Sommer T, Raz A, Posner MI. Testing the efficiency and independence of attentional networks. J Cogn Neurosci 2002;14:340-347.   DOI   ScienceOn
4 Raz A, Buhle J. Typologies of attentional networks. Nat Rev Neurosci 2006;7:367-379   DOI   ScienceOn
5 Jonkman LM, Kemner C, Verbaten MN, Van Engeland H, Kenemans JL, Camfferman G, et al. Perceptual and response interference in children with attention-deficit hyperactivity disorder, and the effects of methylphenidate. Psychophysiology 1999;36:419-429.   DOI   ScienceOn
6 Ridderinkhof KR, Scheres A, Oosterlaan J, Sergeant JA. Delta plots in the study of individual differences: new tools reveal response inhibition deficits in AD/Hd that are eliminated by methylphenidate treatment. J Abnorm Psychol 2005;114:197-215.   DOI   ScienceOn
7 Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628.   DOI   ScienceOn
8 Bedard AC, Martinussen R, Ickowicz A, Tannock R. Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:260-268.   DOI   ScienceOn
9 Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 2004;45:293-305.   DOI   ScienceOn
10 Rhodes SM, Coghill DR, Matthews K. Methylphenidate restores visual memory, but not working memory function in attention deficit- hyperkinetic disorder. Psychopharmacology (Berl) 2004;175:319-330   DOI
11 Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994-1009.
12 Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 2001;13:326-335.   DOI   ScienceOn
13 Nass RD. Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder. Semin Pediatr Neurol 2005; 12:200-216.   DOI   ScienceOn
14 Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005;57:1424-1435.   DOI   ScienceOn
15 Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:191-198.   DOI   ScienceOn
16 Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R. Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol 2003;31:315-127.   DOI   ScienceOn
17 Trommer BL, Hoeppner JA, Zecker SG. The go-no go test in attention deficit disorder is sensitive to methylphenidate. J Child Neurol 1991;6 Suppl:S128-S131.   DOI   ScienceOn
18 Scheres A, Oosterlaan J, Swanson J, Morein-Zamir S, Meiran N, Schut H, et al. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. J Abnorm Child Psychol 2003;31:105-120.   DOI   ScienceOn
19 Konrad K, GÜnther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B. Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial. J Child Adolesc Psychopharmacol 2005;15:180-190.   DOI   ScienceOn
20 de Sonneville LM, Njiokiktjien C, Bos H. Methylphenidate and information processing. Part 1: Differentiation between responders and nonresponders; Part 2: Efficacy in responders. J Clin Exp Neuropsychol 1994;16:877-897.   DOI   ScienceOn
21 Yoon HJ, Yook KH, Jon DI, Seok JH, Hong N, Cho SS, et al. Efficacy and tolerability of osmotic release oral system-methylphenidate in children with attention-deficit hyperactivity disorder according to comorbid psychiatric disorders. J Korean Acad Adolesc Psychiatry 2008;19:147-155.   과학기술학회마을
22 Kim B, Park E. An observational multi-center study for evaluation of efficacy, safety and parental satisraction of methylphenidate-OROS in children with ADHD. J Korean Acad Adolesc Psychiatry 2005;16:279-285.
23 Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113:e206-e216.   DOI   ScienceOn
24 Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657.   DOI   ScienceOn
25 Anderson VR, Keating GM. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatr Drugs 2006;8:319-333.   DOI   ScienceOn
26 Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 2008;46:466-476.   DOI
27 Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002;41:443-449.   DOI   ScienceOn
28 Song DH, Shin DW, Jon DI, Ha EH. Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test. Yonsei Med J 2005;46:34-41.   과학기술학회마을   DOI   ScienceOn
29 Han DH, Lee YS, Na C, Ahn JY, Chung US, Daniels MA, et al. The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder. Compr Psychiatry 2009;50:251-256.   DOI   ScienceOn
30 Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009; 24:95-102.   DOI   ScienceOn
31 Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-216.   DOI   ScienceOn
32 Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89.   과학기술학회마을   DOI   ScienceOn
33 DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: The Guilford Press;1998.
34 Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 1985;21:809-843.
35 Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Dept Health, Education, and Welfare publication;1976.
36 Yoo HK, Lee J, Kang SH, Park EH, Jung J, Kim BN, et al. Standardization of the comprehensive attention test for the Korean children and adolescents. J Korean Acad Child Adolesc Psychiatry 2009;20: 68-75.   과학기술학회마을
37 Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59 Suppl 7:4-16.
38 Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989;28:768-772.   DOI
39 Brams M, Moon E, Pucci M, LOpez FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin 2010;26:1809-1825.   DOI   ScienceOn
40 Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-191.   DOI   ScienceOn
41 Pelham WE Jr, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491-501.
42 Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39.   DOI   ScienceOn
43 Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ. A postmarketing clinical experience study of Metadate CD. Curr Med Res Opin 2002; 18:371-380.   DOI   ScienceOn
44 Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 2006;30: 1225-1245.   DOI   ScienceOn
45 Lee SH, Song DH, Kim BN, Joung YS, Ha EH, Cheon KA, et al. Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder. Yonsei Med J 2009;50:650-655.   DOI   ScienceOn